Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with severe, refractory aplastic anemia have a severe, life threatening disease in their bone marrow. Refractory disease means that disease has come back or not responded after receiving one or more immunosuppressive treatments. High dose chemotherapy followed by bone marrow transplantation (BMT) has been used to treat blood diseases like aplastic anemia but complications from Graft vs Host disease (GVHD) and graft failure have limited the survival for those patients.

Another study done here at Johns Hopkins has shown that in patients with other diseases (blood cancers) some immunosuppressive drugs given after the BMT has decreased how often patients had complications of GVHD and engraftment failure.

This research is being done to find if this approach will help patients with aplastic anemia who have failed other treatments will have better outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia

NCT02224872

Severe Aplastic Anemia Bone Marrow Failure Syndromes

COMPLETED PHASE2

NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia

NCT02833805

Severe Aplastic Anemia Aplastic Anemia Bone Marrow Failure +1 more

COMPLETED PHASE2

Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

NCT06517641

Severe Aplastic Anemia

RECRUITING PHASE2

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

NCT01203722

Hematologic Malignancies

COMPLETED PHASE1/PHASE2

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

NCT00005852

Chronic Myeloproliferative Disorders Graft Versus Host Disease Leukemia +3 more

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Aplastic Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bone Marrow Transplant

Matched sibling, haploidentical or matched unrelated donor bone marrow transplant following chemotherapy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who have refractory or relapsed SAA following treatment with one or more immunosuppressive regimens.
* Age 6 months - 70 years
* Patients must meet medical criteria for myeloablative BMT
* Patients or their parents/guardians and donors must be able to sign consent forms.
* Patients must be geographically accessible and willing to participate in all stages of treatment.

Exclusion Criteria

* Poor cardiac function: left ventricular ejection fraction \<45% as determined by MUGA or ECHO.
* Poor pulmonary function: FEV1 and FVC \<50% predicted.
* Poor renal function
* Positive leukocytotoxic crossmatch
* Women of childbearing potential who currently are pregnant (Β-HCG+) or who are not practicing adequate contraception
* Uncontrolled viral, bacterial, or fungal infections

Minimum Eligible Age

6 Months

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No